Clinical Trial Update: Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial investigating intravenous immune globulin (IVIG) to prevent neonatal infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infant Low Birth Weight
• Infant Newborn
• Infant Premature
• Infant Small For Gestational Age
• Neonatal Sepsis

Drugs mentioned

• Intravenous immune globulin (IVIG) (intravenous immunoglobulin)

Snippet

Sponsor: NICHD Neonatal Research Network | Conditions: Infant, Newborn, Infant, Low Birth Weight | Phase 2, Phase 3 | Status: COMPLETED